Conditions: Cystic Fibrosis
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 70
Healthy volunteers: no

Brief summary:
This Phase IIB proof-of-concept study would examine the effects of an investigational product called N-acetylcysteine (NAC) on the basic processes that cause inflammation in CF lung disease. We hope to learn more about the causes of lung disease in cystic fibrosis by studying the characteristics of the inflammation in the lungs of patients who have CF.

Detailed description:

Arms:
arm 1: Placebo was administered oral tablet TID for 24 weeks. arm 2: Participants received 900 mg of oral N-acetylcysteine TID for 24 weeks.

Interventions: intervention 1: N-acetylcysteine (NAC) intervention 2: Placebo
Intervention descriptions: intervention 1: None intervention 2: None

Protocol document: